1. Clinical Overview

Molecule: Dual-receptor agonist activating GLP-1 + Glucagon receptors

Classification: Dual incretin/glucagon metabolic peptide • Visceral fat mobilization • Anti-NASH candidate • Appetite-suppressing neuroendocrine tool

Clinical Potency: ~15–18% body weight reduction (Phase 2) • NASH histologic improvement • Deep visceral fat reduction with lean mass preservation

Second-generation advanced metabolic peptide succeeding GLP-1 mono-agonists (semaglutide) and GIP/GLP-1 duals (tirzepatide). Unique glucagon pathway enables greater energy expenditure, deeper visceral fat reduction, and thermogenesis activation.

2. Mechanisms of Action

2.1 GLP-1 Agonism

Appetite suppression, slowed gastric emptying, enhanced insulin secretion, suppressed postprandial glucagon, reduced caloric intake.

2.2 Glucagon Receptor Agonism

Hepatic lipid oxidation, enhanced lipolysis, thermogenesis/metabolic rate boost, lean muscle preservation during weight loss.

2.3 Synergistic Dual-Agonism

Appetite suppression + increased energy expenditure. GLP-1 caloric restriction + glucagon fat burning. Broad hepatic and metabolic marker improvements.

3. Clinical Applications

3.1 Obesity & Weight Loss

15.4% average weight loss over 46 weeks (Phase 2). High tolerability. Effective in diabetic and non-diabetic populations.

3.2 Visceral Fat & Body Composition

Deep abdominal fat reductions, improved waist circumference, skeletal muscle preservation.

3.3 NASH & NAFLD

Significant liver fat reductions. Hepatic inflammation & fibrosis improvement (MRI-PDFF & biopsy). Anti-steatotic/anti-fibrotic via glucagon agonism.

3.4 Metabolic Syndrome

Triglycerides, HOMA-IR, fasting insulin improvement. CRP/cytokine reduction. Cardiovascular protective potential.

3.5 Post-GLP-1 Plateau

Effective in GLP-1 resistant patients. Re-engages fat loss in semaglutide/tirzepatide non-responders.

4. Administration & Protocols

Week	Dose (mg/week)
1–4	0.3 mg weekly
5–8	0.6 mg weekly
9–12	1.2 mg weekly
13+	2.4–3.6 mg weekly (therapeutic)

Route: SC (abdomen, thigh, upper arm)
Frequency: Once weekly, consistent day/time
Notes: Titrate slowly for GI tolerance. Hydrate well. Monitor hepatic/metabolic markers.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ 5-Amino-1MQ: Deep visceral fat oxidation — NNMT inhibition + glucagon lipolysis
+ SLU-PP-332: Dual thermogenesis — UCP1 + energy expenditure
+ MOTS-c / SS-31: Mitochondrial enhancement during fat loss — reduces fatigue, protects against burnout
+ CJC-1295 / Ipamorelin: Body recomposition — fat loss + lean mass support

6. Clinical Decision Trees

Candidate Selection

Obesity + visceral adiposity → Strong candidate

NAFLD / NASH → Excellent candidate

Plateaued on GLP-1 → Ideal rescue option

Concerned about muscle loss → Prefer over traditional GLP-1s

Pancreatitis history → Use caution

Pregnancy → Contraindicated

Dosing by Prior Exposure

Incretin-naïve → 0.3 mg/week

GLP-1 experienced → 0.6 mg/week

Post-tirzepatide plateau → 1.2 mg/week + titration

7. Integrated Archetypes

A — Visceral Fat Reduction

Survodutide 2.4–3.6 mg/week + 5-Amino-1MQ + MOTS-c
Lifestyle: Caloric restriction + resistance training

B — Metabolic Syndrome / NASH

Survodutide + SLU-PP-332 + REVIVE™ AM mitochondrial stack + Omega-3, berberine

C — GLP-1 Resistance Rescue

Survodutide 1.2 mg+ weekly + CJC-1295/Ipamorelin + SS-31 or NAD+

8. Safety & Contraindications

Absolute

Personal/family MTC history
MEN2
Pregnancy
Active gallbladder disease

Relative

Pancreatitis history
Severe GERD
Severe hepatic impairment

Side Effects

Common: Nausea, fullness, constipation, fatigue. Rare: Pancreatitis, gallstones, hepatic enzyme elevation.

9. Monitoring

Test	Frequency
CBC, CMP	Baseline, q8–12 weeks
Lipid panel	12 weeks
HbA1c + Insulin	12 weeks
Liver US / MRI-PDFF (NASH)	Baseline + q6 months

Legal Disclaimer

This document is provided solely for educational and informational purposes. Survodutide (BI 456906) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Survodutide

1. Frias, J. P., et al. Survodutide Phase 2 trial in overweight/obesity. Lancet, 402(10397), 1882–1895 (2023).

2. Nahra, R., et al. Phase 1 safety/PK/PD. Obes Sci Pract, 7(3), 319–330 (2021).

3. Boehringer Ingelheim. BI 456906 pipeline overview. Clinical data summary (2022).

4. Nauck, M. A., & Meier, J. J. Incretin therapies: future directions. Diabetologia, 61(5), 873–882 (2018).

5. Rubino, D., et al. GLP-1/glucagon duals for obesity/T2D. Nat Rev Endocrinol, 17, 38–54 (2021).

6. Pettersson, M., et al. Liver fat/fibrosis with dual agonists. Hepatol Commun, early access (2023).

7. Boehringer Ingelheim & Zealand Pharma. BI 456906 Phase 2a NASH results. NCT04771273 (2023).

8. Drucker, D. J. GLP-1 therapeutic potential. Cell Metabolism, 33(4), 740–755 (2021).